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Abstract
Several studies have demonstrated associations between neuropsychiatric disorders, such as attention-deficit/hyperactivity 
disorder (ADHD), and the immune system, including autoimmune diseases. Since ADHD and many autoimmune diseases 
show sex-specific properties, such associations may also differ by sex. Using Norwegian national registries, we performed 
a cross-sectional study based on a cohort of 2,500,118 individuals to investigate whether ADHD is associated with com-
mon autoimmune diseases. Associations between ADHD and autoimmune diseases in females and males were investigated 
with logistic regression and effect modification by sex was evaluated. Several subanalyses were performed. The strong-
est association was found between ADHD and psoriasis in females, adjusted odds ratio (adjOR) = 1.57 (95% confidence 
interval: 1.46–1.68) and males, adjOR = 1.31 (1.23–1.40); p value for interaction < 0.0001. Furthermore, among females, 
ADHD was associated with Crohn’s disease, adjOR = 1.44 (1.16–1.79) and ulcerative colitis, adjOR = 1.28 (1.06–1.54). In 
contrast, males with ADHD had lower odds of Crohn’s disease, adjOR = 0.71 (0.54–0.92), in addition to a trend for lower 
odds of ulcerative colitis, adjOR = 0.86 (0.71–1.03); p values for interaction < 0.0001 and 0.0023, respectively. In a group 
of females where information on smoking and body mass index was available, adjustment for these potential mediators did 
not substantially alter the associations. Our findings support previously reported associations between ADHD and diseases 
of the immune system. The associations differ by sex, suggesting that sex-specific immune-mediated neurodevelopmental 
processes may be involved in the etiology of ADHD.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a neu-
rodevelopmental disorder characterized by the symptoms 
of inattention, hyperactivity and impulsivity. The symptoms 
of this childhood onset condition often persist into adult-
hood [1]. Furthermore, patients often suffer from comorbid 
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psychiatric disorders [2, 3] and face socioeconomic hardship 
[4]. The etiology of ADHD is largely unknown, but in twin 
studies, the heritability of the disorder has been estimated 
to be 70–80%, implicating a strong genetic basis [1, 5, 6]. 
Environmental factors and perinatal factors such as preterm 
birth and growth restriction have also been shown to influ-
ence the development of ADHD [1, 7, 8].
Numerous studies have reported associations between 
neuropsychiatric disorders and immune system abnormali-
ties [9–16]. However, these associations remain uncertain 
[17–19]. Likewise, several immune-related disorders, such 
as atopic dermatitis, asthma, ankylosing spondylitis, ulcera-
tive colitis (UC), juvenile arthritis, autoimmune thyroid dis-
ease and celiac disease have been associated with ADHD 
[20–23]. Additionally, maternal autoimmunity has been 
associated with offspring ADHD, implying that maternal 
immune system dysfunction may affect the in utero environ-
ment and again fetal neurodevelopment [21, 24]. Despite 
the genetic architecture of ADHD being relatively unknown, 
some tentative genetic associations between ADHD and the 
immune system have been noted. For example, a study on 
genetic pathways of ADHD, which was based on genome-
wide association studies (GWAS), found an increased bur-
den of polymorphisms in and around genes involved in toll-
like receptor signaling [25]. These signaling pathways are 
highly involved in the innate immune responses and have 
also been shown to regulate hippocampal plasticity and neu-
rogenesis, and memory formation [26]. Furthermore, the 
single nucleotide polymorphism (SNP) which showed the 
strongest association signal in a recent ADHD GWAS, which 
included more than 20,000 ADHD patients and 35,000 con-
trols, is located in the gene ST3GAL3 [27]. Knockout of the 
ST3GAL3 gene affects both eosinophilic immune responses 
[28] and brain development [29].
ADHD has an approximate male:female ratio of 3:1 dur-
ing childhood and adolescence, which approaches 1:1 in 
adults [1]. Moreover, ADHD displays sex-specific manifes-
tations [30]. For example, females are more often primarily 
affected by inattention, whereas males more often display 
additional symptoms of hyperactivity and impulsivity [31]. 
Likewise, autoimmune diseases have prevalence rates and 
symptom burdens that may differ by sex [32–34]. Interest-
ingly, GWASs have reported SNPs to be associated with an 
autoimmune disease in one sex, but not the other [35] and 
genetic effects being in opposite directions depending on 
sex have been reported [36, 37]. Further, sex hormones are 
believed to have immune-modulating properties, as exempli-
fied by symptom remission of multiple sclerosis and rheuma-
toid arthritis during pregnancy [33, 34]. Neural functioning 
might also be regulated by these hormones, as demonstrated 
by menstrual cycle-associated seizures of certain types of 
epilepsy [38]. Besides, behavior may be affected by sex hor-
mones. For instance, females exposed to elevated prenatal 
androgen levels may develop more aggressive behavior later 
in life as compared to non-exposed females [39], and moreo-
ver, aggressive behavior is associated with ADHD [40].
In sum, if sex-specific genetic pleiotropy, or other sex-
specific mechanisms, underlie any associations between 
ADHD and autoimmunity, these associations may differ 
substantially by sex. In other words, sex could be an effect 
measure modifier.
To further explore possible associations between autoim-
munity and ADHD, and to evaluate whether these associa-
tions vary by sex, we conducted a large cross-sectional study 
based on Norwegian national registries.
Materials and methods
The Medical Birth Registry of Norway (MBRN)
The Medical Birth Registry of Norway (MBRN) was estab-
lished in 1967 to collect medical and familial information 
on parents and births in Norway [41]. Registration in the 
MBRN is mandatory for all pregnancies from 16 completed 
weeks of gestation, and is based on a standardized notifi-
cation form. Maternal smoking habits have been included 
in the registry since December 1998, but is one of few 
variables where mothers can refuse registration. Still, for 
approximately 84% of the births smoking information is reg-
istered. Since 2006, electronic notification of births to the 
MBRN has been introduced gradually, based on standard-
ized extraction from medical records at the delivery units, 
and has included information on maternal height and weight 
before and at the end of pregnancy. However, it was not until 
2014 that electronic notification was in place at all delivery 
units and in 2013, information on height and weight was still 
missing for approximately 36% of the pregnancies.
Data for the current study was obtained for all live births 
in the MBRN from January 1st 1967 to December 31st 2013.
The Norwegian Prescription Database (NorPD)
The Norwegian Prescription Database (NorPD) was estab-
lished in 2004 and provides information on all medical pre-
scriptions dispensed to patients from all Norwegian phar-
macies, and includes the Anatomical Therapeutic Chemical 
Classification System (ATC) codes [42]. Information on 
medication received during hospitalization is not available 
on an individual basis. From 2008, the NorPD has included 
information on diagnostic codes for reimbursed medication 
based on either the International Classification of Primary 
Care (ICPC) or the International Statistical Classification of 
Diseases and Related Health Problems 10th version (ICD-
10), used in specialist health care. From 2004 to 2008, 
the NorPD also included diagnostic codes for prescribed 
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reimbursed medication. However, these diagnostic codes 
were less specific, and therefore not used in this study.
For the present study, information was obtained for all 
dispensed drugs between January 1st 2004 and December 
31st 2015.
The National Education Database
The National Education Database holds information on the 
education of all Norwegian citizens from the age of 16 years. 
The database covers all levels of education from primary 
school to PhD-level. For the present study, data on education 
as registered in 2012 was available.
The National Registry
The National Registry supplied information on emigration 
and dates of death.
Included individuals and record linkage
All individuals registered in the MBRN as born between 
1967 and 2011, who were alive and residing in Norway on 
December 31st 2015, were included in the study. In addi-
tion, the mothers of those registered in the MBRN between 
1998 and 2013, were identified for supplementary analyses 
allowing adjustment for body mass index (BMI) and smok-
ing. Mothers who had died or emigrated by December 31st 
2015 were excluded from these supplementary analyses (see 
below).
All Norwegian citizens have a unique personal identifi-
cation number. This number was used to establish linkage 
between the registries.
ADHD case definition
ADHD cases were defined as all individuals, regardless of 
age, who had been dispensed reimbursed ADHD medication 
(ATC N06BA) (n = 63,721), without reimbursement codes 
for “narcolepsy”, G47 in ICD-10 and “sleep disturbance”, 
P06 in ICPC (n = 407), during 2004–2015.
The remaining population served as the comparison 
group (n = 2,436,397).
Autoimmune diseases
Autoimmune disease cases were defined from reimburse-
ment codes or specific dispensed drugs corresponding to one 
of several predefined and common autoimmune diseases. 
The set of diseases was based on a Danish study describing 
the prevalence of 30 autoimmune diseases [43].
The estimated coverage of the autoimmune disease cases 
was compared with the reported prevalence rates of the auto-
immune diseases in the general population by utilizing Eaton 
et al. 2010 [43] in addition to Norwegian and Swedish prev-
alence studies. Autoimmune diseases where the available 
reimbursement codes were considered too unspecific, that 
had unlikely prevalence estimates, or with less than 1000 
cases in total (< 4 pr 10,000), were excluded. Nine autoim-
mune diseases passed the inclusion criteria (see Table 1) and 
were included in the study.
Table 1  Definitions of ADHD and the autoimmune diseases assessed in the primary analyses
ADHD attention-deficit/hyperactivity disorder, ATC Anatomical Therapeutic Chemical Classification System, ICD-10 International Statistical 
Classification of Diseases and Related Health Problems 10, ICPC International Classification of Primary Care, SLE systemic lupus erythemato-
sus
a  The ICD-10 and ICPC codes for multiple sclerosis are not used in Norway at drug prescribement due to health-regulatory reasons. ATC codes 
for multiple sclerosis-specific drugs therefore defined multiple sclerosis
Disease/disorder Definition of case
ADHD Prescribed and dispensed at least one reimbursed drug once with ATC-code N06BA excluding those with reimburse-
ment code ICD-10 G47 (narcolepsy) or ICPC P06 (sleep disturbance)
Ankylosing spondylitis Prescribed and dispensed at least one drug once with reimbursement code ICD-10 M45
Crohn’s disease Prescribed and dispensed at least one drug once with reimbursement code ICD-10 K50
Iridocyclitis Prescribed and dispensed at least one drug once with reimbursement code ICD-10 H20
Multiple  sclerosisa Prescribed and dispensed at least one drug once with ATC-code L03AB07, L03AB08, L03AB13, L03AX13, 
L04AA23, L04AA27, L04AA31, L04AA34, L04AC01, N07XX07 or N07XX09
Psoriasis Prescribed and dispensed at least one drug once with reimbursement code ICD-10 L40 or ICPC S91
Rheumatoid arthritis Prescribed and dispensed at least one drug once with reimbursement codes ICD-10 M05 or M06
SLE Prescribed and dispensed at least one drug once with reimbursement code ICD-10 M32
Type 1 diabetes Prescribed and dispensed at least one drug once with reimbursement code ICD-10 E10 or ICPC T89, excluding those 
who have been dispensed at least one drug once with ATC-code A10B
Ulcerative colitis Prescribed and dispensed at least one drug once with reimbursement code ICD-10 K51
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Statistical analysis
Possible associations between ADHD and the autoimmune 
diseases were estimated as odds ratios (OR) with 95% con-
fidence intervals (CI) using logistic regression. p values are 
presented uncorrected for multiple testing. The threshold for 
statistical significance was adjusted ad modum Bonferroni 
(p = 0.05 divided by the number of autoimmune diseases 
included in the primary analyses) to p = 0.0056. The thresh-
old for nominal significance was defined as p = 0.05. Data 
management and statistical analyses were performed with R 
[44], RStudio [45] and IBM SPSS [46].
Primary analyses
In the primary analyses, associations between autoimmune 
diseases and ADHD were investigated with adjustment for 
age as a continuous covariate, except for type 1 diabetes 
where age was categorized into four (years of age in 2015: 
4–10; 11–15; 16–20; 21–48). All analyses were stratified by 
sex [1, 30–34]. Effect modification by sex was evaluated on 
a multiplicative scale including an interaction term in the 
logistic regression model, and statistical significance was 
evaluated by Wald test.
Socioeconomic status as defined by maternal education 
was adjusted for as a categorical covariate with three catego-
ries, low (< 10 years of education), medium (10–12 years) 
and high (> 12 years).
Statistically significant associations in the primary analy-
ses were further investigated in supplementary analyses con-
cerning potential confounders, mediators and biases.
Adjustment for smoking and body mass index 
(mother analyses)
Tobacco smoking and BMI may be mediating factors 
between ADHD and autoimmune diseases. Smoking is 
known to be associated with ADHD [47, 48] and has been 
associated with increased risk of several autoimmune dis-
eases in prospective studies [49–51]. The similar applies to 
BMI in ADHD [20, 52] and autoimmunity [53–56]. To con-
duct a sensitivity analysis on whether the associations dis-
covered in the main analyses were mediated mainly through 
smoking and/or BMI, a new study population including data 
on smoking and BMI was defined. The MBRN supplied data 
on smoking for women giving birth from December 1998 to 
2013, and these mothers defined the study population when 
assessing the effect of smoking (from now on referred to 
as the “mother analyses”). Smoking during pregnancy was 
used as a proxy for smoking at linkage. As proxy for BMI at 
linkage, pre-pregnant BMI (kg/m2) of the mothers was used. 
Mothers with registered height below 130 cm or BMI below 
15 or above 60 were set to missing as these values were 
considered biologically implausible. Socioeconomic status 
was defined as the education of the mother in 2012 catego-
rized into three: low (< 10 years), medium (10–12 years) 
and high (> 12 years). For females who had given birth to 
several children, only data from the last registered birth was 
included.
Logistic regression was used to investigate associations 
between ADHD and autoimmune diseases among these 
mothers with and without adjustment for the mother’s smok-
ing habits and with education as covariate. Further, a similar 
logistic regression was conducted with the inclusion of BMI, 
modelled as a continuous covariate, in addition to smok-
ing and education. Substantial attenuation of the estimated 
associations between ADHD and autoimmune diseases when 
adjusting for smoking and BMI, would indicate that much 
of the effect of ADHD on these diseases might be mediated 
through these mediators [57, 58].
Several additional subanalyses were also conducted, 
when possible, to scrutinize statistically significant associa-




We identified a total of 2,500,118 individuals in the MBRN 
fulfilling our inclusion criteria for the primary analyses, 
1,219,669 females and 1,280,449 males.
22,878 (1.9%) of the females had ADHD with the highest 
prevalence among those born in 1993 (3.5%). Of the males, 
40,843 (3.2%) had ADHD, with the highest prevalence 
among those born in 1996 (6.8%) (supplementary Fig. 1). 
ADHD was associated with lower socioeconomic status, as 
defined by maternal educational level (see Table 2).
The total number of patients per autoimmune disease 
ranged from 1197 (5 per 10,000) for systemic lupus ery-
thematosus (SLE) to 62,418 (250 per 10,000) for psoriasis. 
The female-to-male ratios varied across the autoimmune 
diseases, with 42.3% of type 1 diabetes patients being 
female, to 85.5% of SLE patients. All autoimmune diseases 
increased in prevalence with age (supplementary Fig. 1). All 
autoimmune diseases were associated with lower socioeco-
nomic status.
Primary analyses
ADHD was significantly associated with increased odds of 
psoriasis in both females, adjusted (adj) OR = 1.57 (95% CI 
1.46–1.68) and males, adjOR = 1.31 (95% CI 1.23–1.40). 
Associations were significantly stronger for females than 
males, p value for interaction by sex = 4.4 × 10−6.
European Child & Adolescent Psychiatry 
1 3
Sex differences were even larger for Crohn’s disease (CD) 
and UC: Females with ADHD had a significantly higher 
odds of CD, adjOR 1.44 (95% CI 1.16–1.79), and UC, 
adjOR = 1.28 (95% CI 1.06–1.54), than females without 
ADHD. Males with ADHD, on the other hand, seemed pro-
tected, with a lower odds of CD than males without ADHD, 
adjOR = 0.71 (95% CI 0.54–0.92; nominal statistically sig-
nificant), and a tendency to lower odds of UC, adjOR = 0.86 
(95% CI 0.71–1.03). There were significant interaction 
effects between ADHD and sex on the odds for both CD, 
p = 3.6 × 10−5, and UC, p = 0.0023. Despite not reaching 
the threshold for statistical significance, UC was taken to 
supplementary analyses as UC shares many characteristics 
with CD and displayed statistically significant interaction 
effects by sex.
ADHD was further associated with lower odds of anky-
losing spondylitis among females, but only at nominal sta-
tistical significance, adjOR = 0.56 (95% CI 0.32–0.96). 
No association was found for males, adjOR = 1.16 (95% 
CI 0.87–1.55). A nominally significant interaction effect 
between ADHD and sex was noted, p = 0.021.
The primary analyses were also adjusted for prematurity, 
gestational age ≥ 37 weeks or < 37 weeks, with little effect 
on the results (data and results not presented).
See Table 3 for detailed results and Fig. 1 for graphi-
cal representation of the sex-specific associations between 
ADHD and the autoimmune diseases.
Adjustment for smoking and BMI (mother analyses)
512,957 females gave their last birth between December 
1998 and December 31st 2013 during which time smoking 
habits were registered in the MBRN. Of these, 373,672 
(72.8%) were themselves also registered in the MBRN 
at their own birth. There was information on educational 
level for 497,005 (96.9%) of the mothers, and of these, 
information on smoking for 420,050 (84.5%). Of these 
420,050, 73,891 (17.6%) were defined as smokers, and 
additional information on pre-pregnant BMI for was avail-
able for 110,008 (26.2%). The mean and standard devia-
tion of pre-pregnant BMI was 24.4 and 4.8, respectively, 
and 13,304 (12.1%) of these 110,008 females were defined 
as smokers. Thus, data on educational level, smoking and 
BMI was available for 21.4% of all females delivering their 
last recorded birth since the introduction of smoking infor-
mation in December 1998 and up to December 31st 2013. 
See supplementary Fig. 2 for flowchart.
In the mother analyses, ADHD was associated with 
increased odds of psoriasis, adjOR  =  1.62 (95% CI 
1.44–1.81) also after additional adjustment for smoking, 
adjOR = 1.49 (95% CI 1.33–1.67) and BMI, adjOR = 1.29 
(95% CI 1.04–1.60).
ADHD was associated with CD, adjOR = 1.77 (95% CI 
1.23–2.54) and UC, adjOR = 1.87 (95% CI 1.42–2.46). 
Adjustment for smoking did not materially change 
ADHD’s association with CD, adjOR = 1.63 (95% CI 
1.13–2.34) nor UC, adjOR = 1.90 (95% CI 1.45–2.50). 
Similarly, additional adjustment for BMI did not alter the 
ADHD-CD association, adjOR = 2.20 (95% CI 1.24–3.88) 
nor the ADHD-UC association, adjOR = 2.10 (95% CI 
1.30–3.39).
Similar analyses stratified by smoking and overweight, 
BMI < 25 or ≥ 25, were also conducted. The results were 
in line with the presented findings (data and results not 
presented). See Table 4 for detailed results.
Table 2  Characteristics of the study population in the primary analyses
ADHD attention-deficit/hyperactivity disorder, SLE systemic lupus erythematosus
Disease/disorder n (per 10 000) Mean age in 
2015










Total study sample 2,500,118 25.8 1,219,669 (48.8) 23.1 42.0 33.9 0.1
ADHD 63,721 (255) 23.4 22,878 (35.9) 31.5 42.1 25.7 0.7
Ankylosing spondylitis 3504 (14) 37.4 1480 (42.2) 28.9 47.6 23.0 0.5
Crohn’s disease 6292 (25) 32.1 3284 (52.2) 27.6 46.0 25.9 0.5
Iridocyclitis 7596 (30) 34.0 3470 (45.7) 26.3 46.7 26.6 0.4
Multiple sclerosis 3739 (15) 38.1 2621 (70.1) 29.6 49.6 20.5 0.4
Psoriasis 62,418 (250) 33.8 32,190 (51.6) 29.6 46.2 23.7 0.6
Rheumatoid arthritis 8560 (34) 37.2 5662 (66.1) 30.9 47.8 20.8 0.4
SLE 1197 (5) 35.9 1024 (85.5) 30.2 45.6 23.6 0.7
Type 1 diabetes 14,273 (57) 29.5 6041 (42.3) 23.7 46.4 29.6 0.4
Ulcerative colitis 10,960 (44) 34.3 5392 (49.2) 26.3 47.3 26.0 0.4
 European Child & Adolescent Psychiatry
1 3
Fig. 1  Sex-specific associations 
(odds ratios with 95% confi-
dence intervals adjusted for 
age and maternal education) 
between ADHD and the autoim-











































































































Table 3  Associations between ADHD and autoimmune diseases among males and females, and the p-value for the interaction between ADHD 
and sex, with adjustment for age and maternal education
Italics: p < 0.05
Bold and italics: p < 0.0056
ADHD attention-deficit/hyperactivity disorder, CI confidence interval, OR odds ratio, SLE systemic lupus erythematosus
a  Age was categorized into four, years of age in 2015: 4–10; 11–15; 16–20; 21–48 and adjusted for as a nominal covariate
Autoimmune disease Females Males All
Adjusted for age  
n = 1,219,669  
ADHD n = 22,878
Adjusted for age and 
maternal education  
n = 1,207,694  
ADHD n = 22,741
Adjusted for age  
n = 1,280,449  
ADHD n = 40,843
Adjusted for age and 
maternal education  
n = 1,267,647  
ADHD n = 40,544
p value of interaction 
between ADHD and 
sex adjusted for age and 
maternal education  
n = 2,475,341  
ADHD n = 63,285
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) p
Ankylosing spondy-
litis
0.56 (0.32–0.96) 0.56 (0.32–0.96) 1.17 (0.88–1.56) 1.16 (0.87–1.55) 0.021
Crohn’s disease 1.47 (1.18–1.82) 1.44 (1.16–1.79) 0.71 (0.54–0.92) 0.71 (0.54–0.92) 3.6 × 10-5
Iridocyclitis 0.84 (0.64–1.12) 0.83 (0.63–1.10) 1.11 (0.92–1.34) 1.11 (0.92–1.34) 0.084
Multiple sclerosis 1.20 (0.90–1.60) 1.19 (0.90–1.59) 0.95 (0.61–1.46) 0.95 (0.61–1.46) 0.35
Psoriasis 1.60 (1.49–1.72) 1.57 (1.46–1.68) 1.34 (1.25–1.43) 1.31 (1.23–1.40) 4.4 × 10-6
Rheumatoid arthritis 1.05 (0.85–1.28) 1.02 (0.83–1.26) 1.01 (0.78–1.30) 0.98 (0.75–1.26) 0.65
SLE 1.26 (0.82–1.94) 1.25 (0.81–1.93) 1.28 (0.52–3.13) 1.29 (0.53–3.16) 0.98
Type 1  diabetesa 1.00 (0.83–1.19) 1.00 (0.84–1.20) 0.98 (0.87–1.11) 0.98 (0.87–1.11) 0.79
Ulcerative colitis 1.27 (1.06–1.53) 1.28 (1.06–1.54) 0.86 (0.71–1.03) 0.86 (0.71–1.03) 0.0023
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Psoriasis, Crohn’s disease and ulcerative colitis
As a robust positive association between psoriasis and 
ADHD was identified, this association was further exam-
ined, both in regards to psoriasis case definition and age- and 
period effects. The supplementary analyses confirmed the 
results of the primary analyses (see supplementary material 
for both specification of analyses and results).
The diagnoses CD and UC partly overlapped as 2334 
individuals in the primary analyses were defined as hav-
ing both conditions (37.1% of the CD patients and 21.3% 
of the UC patients). Supplementary analyses were con-
ducted after redefining all individuals with both CD and 
UC as having neither. The results confirmed the positive 
associations in females, and the interaction by sex, but the 
negative associations in males were now not present (see 
supplementary material for both specification of analyses 
and results). To assess age- and period effects of ADHD on 
CD and UC, analyses stratified on birth years, 1967–1985 
and 1986–2011, were conducted. For CD, the results were 
in line with the main analyses for both individuals born 
1967–1985 and those born 1986–2011, including the sex-
effects. However, for UC, the positive association in females, 
and negative association in males, were only noted in those 
born 1967–1985. For those born 1986–2011, no associations 
were noted (see supplementary material for further specifi-
cation of analyses and results).
Discussion
In our large cross-sectional study based on population-
wide registries, ADHD was clearly and positively associ-
ated with psoriasis. This association was present regard-
less of sex, but with a significantly stronger association in 
females than males. Furthermore, in females, ADHD was 
positively associated with CD and UC. In contrast, among 
males, ADHD showed a negative association with CD, and 
a similar tendency with UC.
Psoriasis is a skin disorder characterized by red scaly 
skin plaques, papules or patches and is generally consid-
ered an autoimmune disease [43]. The etiology behind 
psoriasis is complex, including environmental and life-
style factors [50, 53, 59] and several genetic risk variants 
have been identified, mainly in and around genes involved 
in the immune response and skin barrier regulation [60]. 
In agreement with our findings, a Danish registry-based 
study noted a possible association between psoriasis and 
ADHD [21]. However, the association was not statistically 
significant (p = 0.09), which may be due to the study’s 
prospective study design where the autoimmune diseases 
had to debut prior to ADHD. In contrast, we utilized a 
cross-sectional design. Moreover, we investigated both 
children and adults, 4–48 years of age at linkage, whereas 
the Danish study only examined children and young adults, 
5–22 years old at linkage, which lead to a smaller study 
sample. In addition, many of the individuals in the Danish 
study were simply too young to have developed psoriasis 
[59] or to have been diagnosed with ADHD [1].
Several different mechanisms may account for the asso-
ciation between ADHD and psoriasis. A recent family-based 
epidemiological study reported a significant genetic correla-
tion between ADHD and psoriasis [61], indicating that there 
could be pleiotropic genetic effects in shared risk pathways. 
For example, complement factor C3 is highly expressed 
in both psoriatic lesions [62] and is important for synap-
tic pruning in the brain [63]. Lifestyle and environmental 
factors associated with ADHD, such as smoking and high 
BMI [20, 47, 48, 52], may also provoke psoriasis [50, 53]. 
However, in our mother analyses, adjustment for these risk 
factors did not attenuate the association, implying alternative 
etiological pathways [57, 58]. Furthermore, emotional and 
social stressors associated with ADHD [4, 64] could perhaps 
trigger psoriasis in predisposed individuals [65].
Table 4  Associations between ADHD and Crohn’s disease, ulcerative colitis and psoriasis among females with adjustment for education, smok-
ing and body mass index
ADHD attention-deficit/hyperactivity disorder, BMI body mass index, CI confidence interval, OR odds ratio
a  Restricted to females with information on smoking
b  Restricted to females with information on BMI
Females Adjusted for  educationa  
n = 420,050  
ADHD n = 5636
Adjusted for education and 
smoking n = 420,050  
ADHD n = 5636
Adjusted for education 
and  smokingb  
n = 110,008  
ADHD n = 1814
Adjusted for education, smoking and 
BMI n = 110,008  
ADHD n = 1814
n OR (95% CI) OR (95% CI) n OR (95% CI) OR (95% CI)
Crohn’s disease 1225 1.77 (1.23–2.54) 1.63 (1.13–2.34) 329 2.27 (1.29–4.01) 2.20 (1.24–3.88)
Psoriasis 14,226 1.62 (1.44–1.81) 1.49 (1.33–1.67) 3919 1.39 (1.12–1.72) 1.29 (1.04–1.60)
Ulcerative colitis 2479 1.87 (1.42–2.46) 1.90 (1.45–2.50) 676 2.00 (1.24–3.22) 2.10 (1.30–3.39)
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CD and UC are both diseases primarily affecting the gas-
trointestinal system [51]. They are considered separate dis-
ease entities, but share many similarities, both clinically and 
etiologically, and are referred to collectively as inflammatory 
bowel disease (IBD). More than 150 genetic risk variants 
have been identified for both, many of which are shared, and 
environmental factors are highly implicated in the etiology 
[51, 66, 67]. In a study from Taiwan, ADHD was associated 
with UC, but not CD [22]. However, the authors did not 
report sex-specific effects, raising the possibility that the 
common estimate may be biased, and that the sex-specific 
effects present in our study, were not identified. Moreover, 
the prevalence-ratio of CD to UC was > 10:1 among the 
controls, indicating possible age-effects in addition to ethnic 
differences.
The increased odds of CD and UC in females with 
ADHD, with a reverse relation in males is striking. In addi-
tion, ADHD females had significantly higher odds of pso-
riasis than ADHD males. Sex, including both hormonal and 
non-hormonal influences, is a key determinant of immune 
system functioning [33, 34], brain development, neural func-
tioning and psychiatric disease [30, 31, 38, 39, 68, 69]. A 
possible etiology for the sex-specific effects may involve 
glial cells, which are neuron-and homeostasis-supportive 
cells of the nervous system with immunomodulatory prop-
erties [33, 68, 70]. Glial cells have been shown to modulate 
sex-determined neurodevelopmental processes, including 
synaptic patterning and neurite pruning [68, 69]. Further, 
there are studies suggesting a role for glial cells located 
along the gut in the etiology of CD and UC, in addition to 
several other gastrointestinal disorders [70].
Genetically, pleiotropic associations between psychiat-
ric disorders and autoimmune diseases have been reported 
[16], and so have sex-specific reverse genetic effects [36, 
37]. Thus, we might hypothesize that the inverse associa-
tions observed in our study could be the result of pleiotropic 
variants, exhibiting sex-specific associations in opposite 
directions in either ADHD and/or IBD. Another potential 
mechanism could be that there is a tendency for more genetic 
variants positively associated with both ADHD and IBD to 
be located on the X-chromosome, while on the Y-chromo-
some, there is a greater burden of variants positively asso-
ciated with ADHD, but negatively associated with IBD 
[35]. As the sex chromosomes have been largely ignored in 
GWASs owing to analytical difficulties, this is an area where 
further research is warranted.
Alternatively, smoking and BMI may play a role in the 
sex-discordant associations between ADHD and IBD [20, 
47, 48, 52, 56]. However, adjustment for these potential 
mediators did not affect the associations much in our mother 
analyses, implying that they are weak mediators. Further, 
smoking has been shown to protect against UC, but confer 
risk for CD [51] and can consequently not easily explain our 
results as we then would have expected a negative associa-
tion between ADHD and UC in females. Regarding BMI, 
prospective studies have only associated premorbid BMI 
with CD and not UC [56], which is not in agreement with 
our findings.
It could be that living with ADHD as a female gives rise 
to more stress, for example through social expectations and 
cultural norms, which again might lead to more autoimmun-
ity [51, 65] and potentially, the sex-specific associations. 
However, one study showed that even though ADHD symp-
toms predispose to more stressful life events, female sex has 
been shown not to predispose to more stressful life events 
among those with ADHD symptoms [64].
Our study has several strengths. The use of compulsory 
population-wide registries minimize the risk of selection 
bias, and may provide the statistical power needed to inves-
tigate potential associations between ADHD and different 
autoimmune diseases. Further, the compulsory registration 
of prescription data protects against follow-up bias. How-
ever, we do not have information on medication given to 
hospital inpatients and nursing homes. Considering that the 
individuals in the primary analyses were all under 50 years, 
and that chronic diseases were investigated, we assume these 
factors to be of minor importance.
Another strength is the possibility to adjust for smoking 
and BMI in the mother analyses to assess mediating effects. 
However, we make the assumption that BMI and smoking at 
last registered pregnancy is “representative” of lifetime sta-
tus up to 2015, which is sub-optimal. As the mother analyses 
were based on females, the generalizability to males could 
be questioned. Nonetheless, we consider it biologically 
unlikely that the positive association between psoriasis and 
ADHD is mediated purely by smoking and BMI in males, 
but not in females. In addition, several types of bias may 
occur as the mother analyses were based on only females 
who had given birth, and many autoimmune diseases are 
associated with reduced fertility [71], again possibly affect-
ing the generalizability of the study. We are also aware that 
adjusting for intermediate variables, as we did in the mother 
analyses, may introduce collider stratification bias due to 
unmeasured variables affecting both smoking, BMI and the 
autoimmune diseases [57, 58]. Caution should therefore be 
exercised in the interpretation of these analyses. Also, we 
had problems with missing data for both smoking and BMI.
In Norway, the prescription of medication used in the 
treatment of ADHD is restricted and the drugs are only pre-
scribed after thorough diagnostic evaluation in specialist 
health care. ADHD patients as defined by dispensed drugs 
is therefore presumably specific for ADHD. Nonetheless, 
we have missed patients who used ADHD medication only 
prior to 2004, and those who have never been prescribed 
medications due to contraindications, mild symptoms or 
patients who declined pharmacological treatment. However, 
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a previous study using similar data from the same period, 
demonstrated that only 17% of registered ADHD patients 
had not received ADHD medication [24]. Furthermore, 
our ADHD case definition includes individuals who in 
2004–2008 were prescribed stimulants for treatment of nar-
colepsy, but as this is a very minor number, it should not 
influence the results.
Dispensed medication and reimbursement codes (ICD-10 
codes and ICPC codes as indications for dispensed medica-
tion) were used as proxies for autoimmune diseases. Thus, 
our definitions of autoimmune diseases may not capture all 
patients. For example, patients with primary-progressive 
multiple sclerosis, which constitute 10–15% of multiple scle-
rosis patients, will often not be identified by our approach as 
until recently there have been limited pharmacological treat-
ment options for this group [72]. Further, the reimbursement 
codes may not always be used correctly. Despite the limita-
tions of our disease identification, we believe that a drug 
prescribed with a reimbursement code, indicates thorough 
diagnostics, especially considering that many of the drugs 
may have serious side effects and are not used without due 
consideration.
We found no robust statistically significant associations 
between ADHD and the autoimmune diseases iridocyclitis, 
rheumatoid arthritis, SLE, ankylosing spondylitis, multiple 
sclerosis or type 1 diabetes. This could be due to a genu-
ine lack of association between these autoimmune diseases 
and ADHD. Nonetheless, it could be that the low share of 
individuals born prior to 1990 who have dispensed ADHD-
medication (supplementary Fig. 1) as compared to those 
born later, may reflect ADHD symptom remission before 
2004 when the NorPD was established, or historical underdi-
agnosis and undertreatment of ADHD. Consequently, these 
ADHD individuals are not identified by our case definition. 
On the contrary, many autoimmune diseases are diagnosed 
later in life. Combined, our study may be inadequate for 
discovering associations between ADHD and autoimmune 
diseases with late debut. This may also partly explain the 
absence of any associations between ADHD and UC among 
individuals born 1985–2011 (supplementary material).
As our study is cross-sectional and we exclude all 
deceased or emigrated individuals, this may constitute a 
source of bias as ADHD is associated with increased mor-
tality [73] and so are many of the autoimmune diseases [74, 
75]. However, we do not believe that such bias underlies the 
findings of our study. First, the increased mortality associ-
ated with ADHD, mostly accidents, is unlikely to differ by 
autoimmune diseases nor constitute a large absolute num-
ber. Second, our cohort is relatively young with the old-
est in the main analyses being 48 years of age at linkage. 
Therefore, most of the cohort is too young for cardiovascu-
lar death, which constitute a large portion of the mortality 
associated with autoimmune diseases [74–76]. In addition, 
the findings regarding CD and psoriasis could be identi-
fied among younger individuals in the birth year-stratified 
analyses. On the other hand, not excluding individuals who 
died or emigrated before the end of study could have lead 
to bias. Individuals who received ADHD medication after 
2004, and thus captured by our study as ADHD patients, 
but developed autoimmune diseases and died or emigrated 
before 2008 would be lost.
Another source of bias could be that ADHD patients, 
already in contact with the health services, may get a diag-
nosis of comorbid diseases more easily than individuals 
who do not have an established link with the health ser-
vices. However, one should then expect increased odds of all 
autoimmune diseases, and for both females and males, which 
was not the case. The symptoms of an autoimmune disease 
could also be mistaken for ADHD symptoms. For example 
the itch of psoriasis could lead to lower sleep quality and 
daytime sleepiness [77, 78], which may be mistaken for the 
impaired attention of ADHD. Yet, one would again expect 
increased odds of all autoimmune diseases.
In conclusion, our study supports previous reports on 
associations between ADHD and autoimmune diseases, 
and adds new knowledge about sex-specific associations and 
even reverse direction by sex for some associations. Our 
results also suggest that these associations are not medi-
ated by smoking or BMI. Overall, our study suggests that 
sex-specific immune-mediated neurodevelopment may play 
a role in ADHD etiology, warranting further investigation. 
Future studies investigating the relationship between autoim-
munity and neuropsychiatric disorders should be aware of 
sex-specific effects.
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